Welcome to our dedicated page for Axsome Therapeutics SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Axsome Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Axsome Therapeutics's regulatory disclosures and financial reporting.
Form 144 Notice Filing for Axsome Therapeutics (NASDAQ: AXSM) details proposed sale of securities by insider Hunter R. Murdock. The filing indicates a planned sale of 6,014 shares of common stock with an aggregate market value of $602,101, to be executed through Charles Schwab & Co.
The shares were acquired through an Employee Stock Option Exercise on June 23, 2025, with payment made via a cashless exercise through broker. The filing reveals significant recent insider trading activity by the same individual over the past three months:
- June 20, 2025: 7,500 shares sold for $768,503
- June 18, 2025: 7,500 shares sold for $756,729
- June 17, 2025: 7,500 shares sold for $751,975
- June 16, 2025: 7,500 shares sold for $768,154
Total outstanding shares reported: 49,236,365. The proposed sale represents a continuation of systematic insider selling pattern, with approximately 30,000 shares sold in the preceding month.
Form 144 Notice filed by Axsome Therapeutics (NASDAQ: AXSM) on June 28, 2025, detailing proposed securities sales under Rule 144. The filing indicates planned sale of 7,500 shares of common stock with an aggregate market value of $768,503 through Charles Schwab & Co.
Key transaction details:
- Securities acquired through employee stock option exercise on June 20, 2025
- Payment made via broker payment for cashless exercise
- Total shares outstanding: 49,236,365
- Planned sale date: June 20, 2025
The filing also discloses previous sales by Hunter R. Murdock in the past 3 months totaling 22,500 shares across three transactions from June 16-18, 2025, with gross proceeds ranging from $751,975 to $768,154. The seller represents no knowledge of undisclosed material adverse information regarding the issuer.
Hunter R. Murdock, General Counsel of Axsome Therapeutics (AXSM), executed a series of pre-planned transactions under a 10b5-1 trading plan over three consecutive days from June 16-18, 2025.
The transactions followed a consistent pattern each day:
- Exercised 7,500 stock options at $29.91 per share
- Immediately sold 7,500 shares at weighted average prices between $100.26-$102.42
Total transaction summary:
- Exercised: 22,500 options
- Sold: 22,500 shares
- Remaining options: 29,883
- Net proceeds per share: approximately $70-72 (sale price minus exercise price)
These transactions were executed according to a pre-approved trading plan, which helps protect executives from insider trading allegations by establishing trade parameters in advance.
Form 144 Notice of Proposed Sale filed for Axsome Therapeutics (NASDAQ: AXSM) details insider trading activity. The filing indicates a proposed sale of 7,500 shares of common stock with an aggregate market value of $756,729, to be executed through Charles Schwab & Co.
The securities were acquired through an employee stock option exercise on June 18, 2025, with payment made via a cashless exercise through broker payment. The filing reveals recent trading activity by the same insider, Hunter R. Murdock, who sold:
- 7,500 shares on June 16, 2025, generating proceeds of $768,154
- 7,500 shares on June 17, 2025, generating proceeds of $751,975
The company currently has 49,236,365 shares outstanding. This Form 144 represents the seller's declaration that they are unaware of any material adverse non-public information regarding the company's operations.